Lotyro Dosage & Drug Information

Concise Prescribing Info

Contents

Erlotinib

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Indications/Uses

1st-line treatment in patients w/ locally advanced or metastatic NSCLC w/ EGFR activating mutations. Switch maintenance treatment in patients w/ locally advanced or metastatic NSCLC w/ EGFR activating mutations & stable disease after 1st-line chemotherapy. Patients w/ locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen. In combination w/ gemcitabine for 1st-line treatment in patients w/ locally advanced, unresectable or metastatic pancreatic cancer.

Dosage/Direction for Use

NSCLC 150 mg daily. Pancreatic cancer 100 mg daily in combination w/ gemcitabine.

Administration

Should be taken on an empty stomach: Take at least 1 hr before or 2 hr after meals.

Contraindications

Hypersensitivity.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01EB02 - erlotinib ; Belongs to the class of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Lotyro FC tab 25 mg

Packing/Price

1's

Form

Lotyro FC tab 100 mg

Packing/Price

1's

Form

Lotyro FC tab 150 mg

Packing/Price

1's

Lotyro

erlotinib

Manufacturer:

MSN Laboratories